SABCS 2017

Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
SABCS 2017
Radius Health, Inc. (Nasdaq:RDUS) today provided an update on data from the Phase 1 005 clinical study of elacestrant (RAD1901), an oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor positive (ER+) breast cancer. The data were presented at a Spotlight Presentation (Abstract 1410) during the 2017 San Antonio Breast Cancer Symposium (SABCS). Elacestrant recently received Fast Track designation from the U.S. Food and Drug Administration. Read More ›
Final Results of NeoMONARCH: A Phase 2 Neoadjuvant Study of Abemaciclib in Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer
SABCS 2017
The combination of abemaciclib plus anastrozole is superior to anastrozole alone in reducing Ki67 across a spectrum of subgroups of patients with hormone receptor (HR)-positive, HER2-negative breast cancer. Read More ›
A Phase 1b Study of Abemaciclib plus Pembrolizumab for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
SABCS 2017
The combination of abemaciclib plus pembrolizumab is safe and effective in women with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer. Read More ›
US Treatment Patterns for Young Women with HR-Positive, HER2-Negative Metastatic Breast Cancer in the Era of CDK4/6 Inhibitors
SABCS 2017
In a retrospective cohort study of more than 17,000 patients with hormone receptor (HR)-positive, HER2-negative breast cancer, changes in the treatment paradigm have more young patients receiving ovarian suppression as part of initial therapy, and patients regardless of age receiving treatment with the CDK4/6 inhibitor palbociclib, whereas a decrease has been seen in use of tamoxifen for younger patients and overall. Read More ›
Phase 1-2 Trial of Pembrolizumab and Either Doxorubicin or an Aromatase Inhibitor for Triple-Negative or HR-Positive Metastatic Breast Cancer
SABCS 2017
The combination of the PD-1 inhibitor pembrolizumab plus either doxorubicin or an aromatase inhibitor may be a feasible approach to treating triple-negative or hormone receptor (HR)-positive metastatic breast cancer. Read More ›
Abemaciclib plus Standard Adjuvant ET versus Standard Adjuvant ET Alone in High-Risk Breast Cancer
SABCS 2017
MonarchE is an ongoing, open-label phase 3 study designed to evaluate invasive disease-free survival in patients with hormone receptor‒positive, HER2-negative advanced breast cancer receiving abemaciclib plus standard-of-care adjuvant endocrine therapy (ET). Read More ›
Abemaciclib for the Treatment of Brain Metastases Secondary to HR-Positive Breast Cancer
SABCS 2017
Abemaciclib demonstrated efficacy and an acceptable safety profile in treating brain metastases in hormone receptor (HR)-positive/HER2-negative breast cancer, but was not effective for brain metastases in HR-positive/HER2-positive breast cancer. Read More ›
The Synergistic Antitumor Activity of Entinostat (MS-275) in Combination with Palbociclib (PD 0332991) in ER-Positive and TN Breast Cancer
SABCS 2017
The combination of the selective histone deacetylase inhibitor entinostat plus a CDK4/6 inhibitor demonstrates greater synergistic antitumor activity against estrogen receptor (ER)-positive breast cancer and triple-negative (TN) breast cancer than either agent alone. Read More ›
Phase 2 Study of the Feasibility and Safety of Radium-223 Dichloride plus Hormonal Therapy and Denosumab for the Treatment of HR-Positive Breast Cancer with Bone-Dominant Metastasis
SABCS 2017
The addition of Ra-223 to hormonal therapy and denosumab is a feasible and safe combination therapy in patients with hormone receptor (HR)-positive breast cancer with bone-dominant metastasis. Read More ›
The Benefit of Abemaciclib in Prognostic Subgroups: An Exploratory Analysis of Combined Data from MONARCH 2 and 3
SABCS 2017
In a subanalysis of the MONARCH 2 and 3 studies, patients with hormone receptor–positive, HER2-negative breast cancer with poor prognostic factors received greater benefit from the addition of abemaciclib to endocrine therapy than those without a poor prognosis. Read More ›

Page 1 of 4

© Amplity Health. All Rights Reserved. Privacy Policy